Mercedes Porosnicu, MD
Internal Medicine · Winston Salem, NCNPI 1417903584
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,842 of the $11,546 with a category attached, or 93.9%. Boehringer Ingelheim International GmbH accounts for 93.9% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2021 at $4,346 and has fallen 83.0% since, to $740 in 2025. Among internal medicine clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 15 payments — averaging $769.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$11K
- Boehringer Ingelheim$513
- E.r. Squibb & Sons, L.L.C.$108
- Sanofi$82
- Merck$3
Across 157 payments — averaging $4293.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$328K
- AstraZeneca$169K
- Merck$71K
- Pfizer$59K
- Boehringer Ingelheim Pharma GmbH & Co.kg$18K
- Astrazeneca UK Limited$14K
- plus $15K from 3 others
What the payments were for
- Consulting fees$10,84294%
- Travel & lodging$2332%
- Food & beverage$4714%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 7 | $10,842 |
| Boehringer Ingelheim | 5 | $513 |
| E.r. Squibb & Sons, L.L.C. | 1 | $108 |
| Sanofi | 1 | $82 |
| Merck | 1 | $3 |
How this compares
$11,546 in reported general payments places this provider in the 95th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 48 | $1,106 |
| Gabapentin | 16 | $391 |
| Ondansetron OdtOndansetron | 27 | $339 |
| Levothyroxine Sodium | 40 | $159 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Winston Salem
- Jamy ArdWinston Salem$293K
- Katharine BattWinston Salem$153K
- Martin MurphyWinston Salem$42K
- John PhippsWinston Salem$32K
- Llewellyn MensahWinston Salem$28K
- Nirmish ShahDurham$862K
- Eugene WrightFayetteville$839K
- Saad UsmaniCharlotte$551K
- Bhakti PaulRaleigh$536K
- Mary KlotmanDurham$478K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.